NCT03106038 is a Phase 1, PHASE2 clinical trial of Nerindocianine for Injection in Intraoperative Ureter Injury, sponsored by Li-Cor, Inc..

Who is sponsoring NCT03106038?

NCT03106038 is sponsored by Li-Cor, Inc..

What drugs are being tested in NCT03106038?

Interventions in NCT03106038: Nerindocianine for Injection.

What condition does NCT03106038 study?

NCT03106038 studies Intraoperative Ureter Injury.

Is NCT03106038 still recruiting?

NCT03106038 is currently completed. Last updated 26 November 2019.

Last reviewed 2019-11-26 · How we verify

NCT03106038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

Completed Phase 1, PHASE2 Last updated 26 November 2019

What this trial tests

Phase 1, PHASE2 trial testing Nerindocianine for Injection in Intraoperative Ureter Injury in 41 participants. Completed in 19 November 2018.

Timeline

26 April 2017

Primary endpoint
19 November 2018

19 November 2018

Quick facts

Lead sponsor	Li-Cor, Inc.
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	41
Start date	26 April 2017
Primary completion	19 November 2018
Estimated completion	19 November 2018
Sites	1 location across United States

Drugs / interventions tested

Nerindocianine for Injection — full drug profile →

Conditions studied

Intraoperative Ureter Injury — all drugs for Intraoperative Ureter Injury →

Sponsor

Li-Cor, Inc. — full company profile →

Who can join

19 and older, female only, with Intraoperative Ureter Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to study the safety and efficacy of an investigational imaging agent for delineation/visualization of urologic anatomy in the setting of minimally invasive surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Fluorescence Image-Guided Surgery - a Perspective on Contrast Agent Development.
Barth CW, Gibbs SL. · · 2020 · cited 79× · PMID 32255887 · DOI 10.1117/12.2545292
Currently available and experimental dyes for intraoperative near-infrared fluorescence imaging of the ureters: a systematic review.
Slooter MD, Janssen A, Bemelman WA, Tanis PJ, et al · · 2019 · cited 35× · PMID 31030340 · DOI 10.1007/s10151-019-01973-4
Intraoperative ureter identification with a novel fluorescent catheter.
Barberio M, Al-Taher M, Felli E, Ashoka AH, et al · · 2021 · cited 14× · PMID 33627768 · DOI 10.1038/s41598-021-84121-z

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03106038 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Li-Cor, Inc.
Last refreshed: 26 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03106038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing